Oddity Tech's second-quarter sales fell 25% to $181 million, just ahead of Wall Street's target.
Earnings fell from $0.92 per share to $0.20, topping analyst estimates by a penny.
The Il Makiage brand is working through a painful algorithm shift at a key advertising partner.
Shares of Oddity Tech (NASDAQ: ODD) absolutely skyrocketed on Wednesday. The Israel-based maker of data-driven beauty products reported earnings early this morning, narrowly exceeding Wall Street's estimates. The stock closed 26.5% higher, having soared as much as 41.6% just after the market open.
Image source: Getty Images.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Those jumps are not typos or miscalculations, but I was also serious about the narrow surprises. Oddity Tech's Q2 2026 sales fell 25% year over year, landing at $181 million. Earnings per share dropped from $0.92 to $0.20. The average analyst targets were $176.5 million and $0.19 per share, respectively. Furthermore, management offered its first revenue guidance for the 2026 fiscal year, targeting a year-over-year drop of approximately 19%.
Oddity Tech's mellow report sparked an odd market reaction. Investors focused on solid results for the SpoiledChild anti-aging products and the Methodiq telehealth service, while the Il Makiage makeup division is working through algorithm shifts with a key marketing partner.
To be fair, the bright spots were brilliant. The SpoiledChild brand is on track to reach nearly $350 million in total sales in 2026, 35% above the previous year. The Methodiq line is just a few months old, but it is tracking ahead of SpoiledChild's early results. And the Il Makiage issues are slowly resolving, setting the company up for stronger results in 2027 and beyond.
But this is an odd duck on Wall Street. Oddity Tech sells cosmetics the way a software company sells software, and it owns a Boston biotech lab to make the ingredients. And it runs sales the way Lemonade sells insurance: through an online quiz to define your beauty needs. There are also echoes of Stitch Fix's try-before-you-buy tactics.
Results are lumpy, the stock is volatile, and some 23% of its shares are sold short. And even after Wednesday's 26.5% gain, it's still down 74% over the last 52 weeks. This jump is more of a rebound than a victory march.
Oddity Tech is an incredibly interesting business, but it runs a fragile marketing strategy. Every brand, including the healthy ones, depends on the same paid social funnel, and one algorithm change took first orders down by 40%. I don't mind watching this turnaround story from the sidelines.
Before you buy stock in Oddity Tech, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Oddity Tech wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $414,015!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,385,459!*
Now, it’s worth noting Stock Advisor’s total average return is 960% — a market-crushing outperformance compared to 213% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of September 9, 2026.
Anders Bylund has positions in Lemonade. The Motley Fool has positions in and recommends Lemonade. The Motley Fool recommends Stitch Fix. The Motley Fool has a disclosure policy.